这些化合物的衍生物包括表柔比星和伊达比星。
Derivatives of these compounds include epirubicin and idarubicin.
目的评估表柔比星为主的联合方案治疗非霍奇金淋巴瘤的疗效。
Objective to evaluate the treatment of non-Hodgkin s lymphoma with combined regimen containing epirubicin as the main drug and to find an effective regimen with low toxicity.
目的：探究参附注射液联合表柔比星和紫杉醇治疗三阴性乳腺癌的临床疗效。
Objective To explore the clinical curative effect of Shenfu Injection combined with epirubicin and paclitaxel in treatment of triple negative breast cancer.
目的研究两种方法制备的葡聚糖-表柔比星偶合物的稳定性及体外细胞毒活性。
ABSTRACT: OBJECTIVE To study the stability and in vitro cytotoxicity of two kinds of dextran-epirubicin conjugates .
目的：研究表柔比星加紫杉醇新辅助化疗方案治疗乳腺癌的近期疗效及毒副反应。
Purpose: To study the short-term efficacy and toxicity of the neoajuvant chemotherapy with epirubicin (EPI) plus paclitaxel( TAX) in treatment of patients with breast cancer.
目的研究两种方法制备的葡聚糖-表柔比星偶合物的稳定性及体外细胞毒活性。
OBJECTIVE To study the stability and in vitro cytotoxicity of two kinds of dextran-epirubicin conjugates.
目的：观察国产表柔比星为主的联合化疗方案治疗非霍奇金淋巴瘤、乳腺癌、非小细胞肺癌的疗效和不良反应。
Objective:To observe the efficacy and toxicity of domestic epirubicin in treatment of non Hodgkin's lymphoma, breast cancer, and non small cell lung cancer.
目的：观察国产表柔比星为主的联合化疗方案治疗非霍奇金淋巴瘤、乳腺癌、非小细胞肺癌的疗效和不良反应。
Objective:To observe the efficacy and toxicity of domestic epirubicin in treatment of non Hodgkin's lymphoma, breast cancer, and non small cell lung cancer.
应用推荐